Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

The NR2B subunit-selective NMDA receptor antagonist, CP-101,606 reduces pain intensity in patients with central and peripheral neuropathic pain

The NR2B subunit-selective NMDA receptor antagonist, CP-101,606 reduces pain intensity in patients with central and peripheral neuropathic pain. Society for Neuroscience. 2003.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.